Scarlet Therapeutics Secured DARPA Smart Cell Contract
The firm will lead a consortium to develop responsive red blood cells under a new $14 million research agreement.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Should the government prioritize funding for experimental biological research programs like smart red blood cells?
Scarlet Therapeutics has signed a $14 million agreement with DARPA to engineer adaptive smart red blood cells. The program aims to create long-acting medicines that sense and respond to physiological changes in the body.
Why it matters
This research seeks to revolutionize medicine by utilizing engineered blood cells as dynamic, autonomous delivery systems for therapeutics. The ability to monitor and react to biological shifts in real-time could fundamentally alter how complex health conditions are managed.
The program, designated HR0011-26-9-E150, integrates red blood cell biology, synthetic biology, and computational design. The effort focuses on building sensing and control mechanisms directly into the cells to enable automated physiological responses.
The players
Scarlet Therapeutics
A biotechnology firm headquartered in Bristol, United Kingdom, that specializes in synthetic red blood cell technology.
DARPA
The Defense Advanced Research Projects Agency is a federal organization responsible for developing emerging technologies for military and national security applications.
University of Bristol
A research-intensive institution based in the United Kingdom that serves as a key consortium partner and contributor to the cellular technology being developed.
Northwestern University
A private research university located in Illinois that is participating as a member of the project consortium.
Unicorn Biotechnologies
A biotechnology entity that is providing expertise as part of the multidisciplinary team assembled for the DARPA program.
The details
Scarlet Therapeutics will lead a multidisciplinary team including the University of Bristol, Northwestern University, and Unicorn Biotechnologies. The consortium will combine automated cell manufacturing techniques with synthetic biology to enhance the functionality of red blood cells for medical use.
Timeline
Scarlet Therapeutics announced the $14 million DARPA agreement on September 23, 2026.
The Big Picture
This project follows the precedent set by the DARPA Biological Technologies Office research initiatives. It extends the agency's history of funding high-risk, high-reward synthetic biology projects aimed at creating autonomous medical solutions.
While the technology is currently in the experimental stage, success could eventually lead to new medical treatments that automatically adjust dosages or release medicine within the body. Patients with chronic conditions may see simplified treatment regimens in the future.
The takeaway
This partnership marks a significant step toward embedding synthetic intelligence into the human circulatory system. Future research will focus on whether these engineered cells can reliably execute control mechanisms within complex biological environments.
Further reading
Explore the latest developments in synthetic biology within the Biotech section.
Live Poll
Should the government prioritize funding for experimental biological research programs like smart red blood cells?
